subsequent to the Initial Development Activities, [[Organization A:Organization]] shall supply pre-clinical and clinical requirements of the Licensed Compounds or Licensed Products and placebo or other comparators for use by [[Organization A:Organization]] in the Development of Licensed Compounds or Licensed Products as contemplated in the Development Plan. If the Parties are unable to agree upon a supply arrangement for the initial Phase 3 campaign pursuant to the right of first negotiation set forth in this Section 3.5.1 and in order to ensure the continuity of Development of the Licensed Compound, as reasonably requested by [[Organization A:Organization]], ​ shall and shall use Commercially Reasonable Efforts to cause its Third Party Providers to enter into supply and any other relevant agreements with [[Organization A:Organization]] to facilitate the transition of clinical supply responsibility to [[Organization A:Organization]] after [[Organization A:Organization]] proceeds with the In-Licensing, which agreements shall provide for Phase 3 and commercial clinical supply materials. Due to the lead-time for manufacturing, the initial Phase 3 clinical supply materials and associated manufacturing activities are set forth and included in the Initial Development Plan and Budget.

subsequent toSupply. For the Initial Development Activities, [[Organization A:Party:Organization]] shall supply pre-clinical and clinical requirementsrequirements, including the requirement for the initial Phase 3 campaign, of the Licensed Compounds or Licensed Products and placebo or other comparators for use by [[Organization A:Party:Organization]] in the Development of Licensed Compounds or Licensed Products as contemplated in the Initial Development Plan. IfPlan and Budget; provided, that ​ agrees [[Organization A:Organization]] (or its Affiliate) shall have a right of first negotiation to Manufacture the Licensed Compounds or Licensed Products and placebo or other comparators for the initial Phase 3 campaign and the Parties shall negotiate in good faith the terms and conditions on which [[Organization A:Organization]] (or its Affiliate) would supply such requirements. In the event, despite good faith negotiations, the Parties are unable to agree upon athe terms and conditions of the supply arrangement for the initial Phase 3 campaign pursuant to the right of first negotiation set forth in this Section 3.5.1 and in order to ensure the continuity of Development of the Licensed Compound, as reasonably requested by [[Organization A:Organization]],campaign, then ​ shallwould be free to negotiate and shall use Commercially Reasonable Efforts to cause its Third Party Providers to enter into a supply and any other relevant agreementsarrangement with [[Organization A:Organization]] to facilitate the transition of clinical supply responsibility to [[Organization A:Organization]] aftera Third Party. After [[Organization A:Organization]] proceeds with the In-Licensing, which agreements shall provideLicensing and for Phase 3 and commercial clinical supply materials. Due to the lead-time for manufacturing, the initial Phase 3 clinical supply materials and associated manufacturingDevelopment activities are set forth and included in the Initial Development Plan and Budget.CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[...​...]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED.